



Swiss Innovators Yearbook

► MEDION DIAGNOSTICS

Medion Diagnostics has developed a new device the size of a credit card that can quickly and accurately determine an individual's blood group. Contrary to other such devices on the market, Medion Diagnostics' MDmulticard does not require a centrifuge and can thus run without electricity. For one person, ten different blood groups including the RH factor can be ascertained in just five minutes. The data analysis is simple and results remain visible for several days. This device is of great interest to emergency medical services, blood donor centres, hospital laboratories and organisations that deal with natural catastrophes.

This important innovation earned Medion Diagnostics a special Jury prize from the Fribourg Development Agency in 2005. The prize is worth CHF 5000. The Fribourg Innovation contest has been held every two years since 1991 and was founded in order to promote innovation and development in the canton.

Medion Diagnostics is a young company based in Düdingen that focuses on immunohematology. The company was founded in 2001. In recent years a new research and development program has been initiated. The MDmulticard, three and a half years in the making, is a product of this ambitious research program. The hard work is paying off as the product has already caught the interest of the German Red Cross and, most importantly, hospitals. In 2005, a management buy-out took place and the company was taken over by the Managing Directors, Dr. Peter Schwind and Joe Wilms.



Medion Diagnostics

NAME

Medion Diagnostics

CEO

Dr. Peter Schwind & Joe Wilms

CATEGORY

Immunohematology

TEAM

39

CREATED

2001

AWARD

2005

Fribourg Canton Innovation Prize

ADDRESS

Bonnstrasse 9

3186 Düdingen

T. +41 26 492 85 11

CANTON

FR

WEBSITE, EMAIL

www.medion-diagnostics.com

peter.schwind@medion-diagnostics.com

CONTACT

Dr. Peter Schwind



In light of MDmulticard's market potential, Medion Diagnostics hopes to mechanise their production facility. This way, the company will be able to produce up to 3 million devices per year as opposed to the 250'000 they are currently producing. Medion Diagnostics is focusing on developing other products as well as marketing the ones that have already passed the prototype phase. The MDmulticard should reach the market stage by the middle of 2006. Future goals for the company include the development of an entire range of blood analysis cards that could be used together to carry out a patient's full medical examination.